How have APLIF shares performed in 2024?

Appili Therapeutics' stock was trading at $0.0265 on January 1st, 2024. Since then, APLIF shares have increased by 10.2% and is now trading at $0.0292. View the best growth stocks for 2024 here .

Are investors shorting Appili Therapeutics?

Appili Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 86,900 shares, an increase of 16.5% from the February 29th total of 74,600 shares. Based on an average daily trading volume, of 272,100 shares, the short-interest ratio is presently 0.3 days. View Appili Therapeutics' Short Interest .

When is Appili Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024. View our APLIF earnings forecast .

How were Appili Therapeutics' earnings last quarter?

Appili Therapeutics Inc. (OTCMKTS:APLIF) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The business earned $0.36 million during the quarter.

How do I buy shares of Appili Therapeutics?

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:APLIF

Appili Therapeutics (APLIF) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free APLIF Stock Alerts

$0.03

0.00 (0.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.03
▼
$0.03
50-Day Range: $0.02
▼
$0.04
52-Week Range: $0.02
▼
$0.08

Volume: 3,030 shs
Average Volume: 449,634 shs
Market Capitalization: $3.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Headlines Short Interest

Get Appili Therapeutics alerts:

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Appili Therapeutics Stock (OTCMKTS:APLIF)

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

APLIF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APLIF Stock News Headlines

April 4, 2024 | uk.investing.com

Aditxt to acquire Appili Therapeutics in strategic move

April 2, 2024 | businesswire.com

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

April 2, 2024 | finance.yahoo.com

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

April 2, 2024 | globenewswire.com

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

March 12, 2024 | globenewswire.com

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

February 14, 2024 | finanznachrichten.de

Appili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

February 14, 2024 | seekingalpha.com

Appili Therapeutics reports Q3 results

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

February 13, 2024 | finance.yahoo.com

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

February 13, 2024 | globenewswire.com

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

February 3, 2024 | morningstar.com

Appili Therapeutics Inc Ordinary Shares

December 6, 2023 | finance.yahoo.com

APLIF: ATI-1701 Program Awarded Additional US$6.6 Million in Funding…

November 14, 2023 | msn.com

Appili Therapeutics GAAP EPS of -C$0.01

November 13, 2023 | finance.yahoo.com

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

October 25, 2023 | finance.yahoo.com

Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

October 5, 2023 | finance.yahoo.com

APLIF: FDA Approves LIKMEZ™ (ATI-1501)…

September 27, 2023 | ca.finance.yahoo.com

UPDATE 2-Canada's Appili gets US FDA approval for oral antibiotic solution

September 27, 2023 | finance.yahoo.com

Appili Therapeutics Presents at the 10th International Tularemia Conference

September 25, 2023 | marketwatch.com

Appili Therapeutics' Licensing Partner Gets FDA Approval for Metronidazole Oral Suspension

September 25, 2023 | stockhouse.com

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral Suspension

September 25, 2023 | markets.businessinsider.com

Appili Therapeutics Says FDA Approves LIKMEZ Metronidazole Oral Suspension

September 25, 2023 | finance.yahoo.com

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension

September 25, 2023 | finance.yahoo.com

UPDATE 1-Canada's Appili gets US FDA approval for oral antibiotic solution

July 17, 2023 | finance.yahoo.com

APLIF: Executes Initial Contract with USAFA for Development of ATI-1701…

June 29, 2023 | finance.yahoo.com

Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.

June 28, 2023 | finance.yahoo.com

Appili Therapeutics Full Year 2023 Earnings: CA$0.081 loss per share (vs CA$0.38 loss in FY 2022)

See More Headlines

Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 6/21/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:APLIF
CUSIP: N/A
CIK: N/A
Web: www.appilitherapeutics.com
Phone: 902-442-4655
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,990,000.00
Net Margins: -456.86%
Pretax Margin: -452.87%
Return on Equity: N/A
Return on Assets: -229.96%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.46
Quick Ratio: 0.46

Sales & Book Value

Annual Sales: $280,000.00
Price / Sales: 12.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.05) per share
Price / Book: -0.58

Miscellaneous

Outstanding Shares: 121,270,000
Free Float: 106,908,000
Market Cap: $3.54 million
Optionable: Not Optionable
Beta: -0.30

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Donald D. Cilla Jr.
M.B.A., Pharmd, CEO, President & Director
Mr. Kenneth G. Howling
Chief Financial Officer
Dr. Gary S. Nabors Ph.D.
Chief Development Officer

Key Competitors

View All Competitors

APLIF Stock Analysis - Frequently Asked Questions

How have APLIF shares performed in 2024?: Appili Therapeutics' stock was trading at $0.0265 on January 1st, 2024. Since then, APLIF shares have increased by 10.2% and is now trading at $0.0292.
View the best growth stocks for 2024 here.
Are investors shorting Appili Therapeutics?: Appili Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 86,900 shares, an increase of 16.5% from the February 29th total of 74,600 shares. Based on an average daily trading volume, of 272,100 shares, the short-interest ratio is presently 0.3 days.
View Appili Therapeutics' Short Interest.
When is Appili Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024.
View our APLIF earnings forecast.

How were Appili Therapeutics' earnings last quarter?: Appili Therapeutics Inc. (OTCMKTS:APLIF) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The business earned $0.36 million during the quarter.
How do I buy shares of Appili Therapeutics?: Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:APLIF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial